By considering stability as part of the cell line selection and cell banking paradigm, we can ensure that instability problems are not observed during clinical or commercial manufacturing.
Megan Hone
Advertisement
Megan Hone is scientist II in the cell and molecular sciences group in the department of Drug Substance Development at Wyeth Biopharma
Articles by Megan Hone
Advertisement
Latest Updated Articles
Advertisement
Advertisement